Epidemiology, Healthcare Resource Utilization, and Costs of Ulcerative Colitis and Crohn's Disease Patients in Taiwan: A National Health Insurance Research Database (NHIRD) Study

Speaker(s)

Tang CH1, Wei A2, Newson RS3, Ng KJ4, Shen D5, Wang B5
1Taipei Medical University, Taipei, Taiwan, 2Eli Lilly and Company (Taiwan), Taipei, Taiwan, 3Eli Lilly and Company, Sydney, Australia, 4Eli Lilly and Company, Indianapolis, IN, USA, 5Elysia Group Ltd., Taipei, Taiwan

Presentation Documents

OBJECTIVES: The objective of this study was to evaluate Ulcerative Colitis (UC) and Crohn's Disease (CD) patient profiles, healthcare resource utilization (HCRU), and costs using Taiwan’s NHIRD.

METHODS: We conducted a cross-sectional analysis annually from 2016 through 2020 to identify patients using catastrophic illness certificates issued for UC or CD. We examined the incidence, prevalence, gender, and age of patients. We also conducted a subgroup analysis of patients treated with targeted therapies. A longitudinal analysis indexed UC or CD patients in 2017-2018 to estimate their HCRU and annual costs (in NTD).

RESULTS: Prevalent patients for UC and CD increased each year from 2016 to 2020. In 2020, there were 1623 CD and 4342 UC patients. On average, there were 162.4 new CD and 335.4 new UC patients each year. CD patients were predominantly male (67.27%), with the 20-39 age group accounting for 45.91% of all patients. UC patients skewed older, with those aged 40 and above comprising 70.06% of all patients. For the targeted therapy subgroup, there were 266 CD patients in 2016, increasing to 630 in 2020. For UC patients, there were 92 patients in 2016 increasing to 281 in 2017 and 672 in 2020.

In the first year of follow-up, 31.49% of CD patients had a disease-related hospitalization, with a mean hospital stay of 20.43 days. Disease-related costs were 180,035 NTD, with medication and non-medication costs as 137,618 NTD and 42,417 NTD, respectively. For UC patients, 17.93% had a disease-related hospitalization, with a mean stay of 11.87 days. Disease-related costs were 97,847 NTD, with medication and non-medication costs as 77,033 NTD and 20,814 NTD, respectively.

CONCLUSIONS: This study provides valuable insights into the epidemiology, healthcare resource utilization, and costs of UC and CD patients in Taiwan, which can inform healthcare policy and resource allocation strategies.

Code

RWD42

Topic

Real World Data & Information Systems, Study Approaches

Topic Subcategory

Health & Insurance Records Systems

Disease

Gastrointestinal Disorders, No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)